Lecanemab (brand name Leqembi; development code BAN2401) is a humanized IgG1 monoclonal antibody therapeutic developed by Eisai Co., Ltd. in partnership with Biogen Inc. for the treatment of early Alzheimer's disease (AD). Approved by the U.S. Food and Drug Administration (FDA) in January 2023, lecanemab represents a landmark achievement as the first amyloid-targeting antibody to demonstrate clinically meaningful slowing of cognitive decline in a Phase III clinical trial[@van2023].
This entity profile provides a comprehensive overview of lecanemab as a therapeutic entity within the NeuroWiki knowledge base, covering its molecular characteristics, mechanism of action, clinical development, and position within the landscape of Alzheimer's disease therapeutics. For detailed clinical trial data, efficacy analyses, and safety profiles, refer to the dedicated therapeutics page: Lecanemab (Leqembi) — Therapeutics.
Lecanemab is a humanized IgG1 monoclonal antibody engineered for optimal binding to amyloid-beta (Aβ) protofibrils. The antibody was developed using Ei's proprietary platform, which employs a combination of phage display and immunization strategies to identify antibodies with specific binding profiles[@honma2023].
Key molecular properties:
| Property | Value |
|---|---|
| Antibody type | Humanized IgG1 |
| Molecular weight | ~150 kDa |
| Target | Aβ protofibrils (soluble oligomers) |
| Affinity (Kd) for protofibrils | ~10⁻¹⁰ M |
| Affinity (Kd) for monomers | Significantly lower |
| Fc region | Native (not engineered) |
One of lecanemab's distinguishing features is its preferential binding to soluble Aβ protofibrils rather than monomers or mature amyloid plaques. Protofibrils are intermediate-length Aβ aggregates (approximately 100-600 kDa) that have been identified as the most toxic form of Aβ in experimental models. Research has demonstrated that protofibrils are 10-100 times more toxic per molecule than monomeric Aβ, making them an attractive therapeutic target[@mcdade2022].
The selectivity for protofibrils differentiates lecanemab from other anti-amyloid antibodies:
This unique binding profile allows lecanemab to neutralize the most toxic circulating aggregates before they can cause widespread neuronal damage, while also facilitating clearance of existing amyloid burden.
Lecanemab exerts its therapeutic effects through multiple complementary mechanisms:
1. Direct Neutralization of Toxic Protofibrils
By binding to soluble Aβ protofibrils, lecanemab neutralizes their neurotoxicity and prevents their interaction with neurons, synapses, and glia. This prevents downstream downstream signaling events that lead to synaptic dysfunction and neuronal death.
2. Fcγ Receptor-Mediated Clearance
The antibody-opsonized Aβ complexes engage Fcγ receptors on microglia, triggering microglial phagocytosis and lysosomal degradation. This represents the primary clearance mechanism for lecanemab-bound amyloid[@logovinsky2024].
3. Peripheral Sink Effect
Binding of lecanemab to plasma Aβ creates a concentration gradient that promotes efflux of Aβ from the brain parenchyma into the peripheral circulation. This "peripheral sink" mechanism contributes to overall amyloid reduction.
4. Plaque Destabilization
Evidence suggests lecanemab may also destabilize existing amyloid plaques, facilitating their conversion to soluble aggregates that can be cleared by the mechanisms described above.
Lecanemab's mechanism is intimately connected to microglial biology. The antibody's efficacy depends on functional microglial phagocytosis, which involves several microglial receptors and pathways:
This relationship explains why genetic variants affecting microglial function (such as TREM2 risk variants) may influence individual patient responses to lecanemab therapy.
Lecanemab was discovered through a collaboration between Eisai and BioArctic. Early preclinical studies demonstrated:
Phase I clinical trials established:
The Phase IIb study enrolled 856 patients with early AD (MCI due to AD or mild AD dementia)[@mcdade2022]:
The pivotal Phase III Clarity-AD trial enrolled 1,795 patients with early AD across 233 sites in North America, Europe, and Asia[@van2023]:
Following FDA approval, development continues with:
| Region | Status | Date |
|---|---|---|
| United States | Full FDA approval | January 2023 |
| Japan | Approved | January 2023 |
| South Korea | Approved | May 2023 |
| China | Approved | October 2023 |
| Australia | Approved | December 2023 |
| United Kingdom | Under review | - |
| European Union | Under review | - |
Lecanemab is indicated for the treatment of early Alzheimer's disease, specifically:
Patients must have confirmed amyloid pathology via PET scan or CSF biomarkers before initiating treatment.
| Feature | Lecanemab | Donanemab | Aducanumab |
|---|---|---|---|
| Target | Protofibrils | Plaques | Monomers/plaques |
| Dosing | 10 mg/kg biweekly | Weight-based | 10 mg/kg monthly |
| Amyloid reduction | ~81% | ~70% | ~60% |
| CDR-SB benefit | 0.45 | 0.70 | 0.39 |
| ARIA-E rate | 12.6% | 24% | 35% |
Lecanemab occupies a unique position in the AD therapeutic landscape:
Lecanemab's approval validates the amyloid cascade hypothesis and establishes disease-modifying therapy as the standard for AD treatment. The demonstration that amyloid removal correlates with clinical benefit has accelerated development of additional anti-amyloid and anti-tau therapeutics.
Optimal candidates for lecanemab therapy meet the following criteria:
Patients receiving lecanemab require regular monitoring:
| Risk Factor | Impact |
|---|---|
| APOE ε4 homozygosity | Highest ARIA risk |
| APOE ε4 heterozygosity | Moderate ARIA risk |
| Prior cerebral microhemorrhages | Increased risk |
| Anticoagulant use | Increased hemorrhage risk |
| Trial | Phase | Population | Status | Key Results |
|---|---|---|---|---|
| Study 201 | IIb | Early AD (n=856) | Complete | Dose-dependent efficacy |
| Clarity-AD | III | Early AD (n=1,795) | Complete | Primary endpoint met |
| Clarity-OLE | III | Previous lecanemab pts | Ongoing | Long-term safety/efficacy |
| AHEAD 3-45 | III | Preclinical AD | Recruiting | Prevention trial |
Despite lecanemab's approval, several important questions remain:
Active research areas include: